Clinical Trial

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Study acronym: GLOW
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07428746
Lead Sponsor Emory University
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Diabetes Mellitus, Type 2
Enrollment 20 participants
Start Date 2026-05-07
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-03